Bok R - Search Results

1

Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer.

Small EJ, Frohlich MW, Bok R, Shinohara K, Grossfeld G, Rozenblat Z, Kelly WK, Corry M, Reese DM. Small EJ, et al. Among authors: bok r. J Clin Oncol. 2000 Nov 1;18(21):3595-603. doi: 10.1200/JCO.2000.18.21.3595. J Clin Oncol. 2000. PMID: 11054432 Clinical Trial.

2

Quantitative characterization of the binding of plasminogen to intact fibrin clots, lysine-sepharose, and fibrin cleaved by plasmin.

Bok RA, Mangel WF. Bok RA, et al. Biochemistry. 1985 Jun 18;24(13):3279-86. doi: 10.1021/bi00334a031. Biochemistry. 1985. PMID: 3161540

3

Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.

Small EJ, Baron A, Bok R. Small EJ, et al. Among authors: bok r. Cancer. 1997 Nov 1;80(9):1755-9. doi: 10.1002/(sici)1097-0142(19971101)80:9<1755::aid-cncr9>3.0.co;2-d. Cancer. 1997. PMID: 9351544 Clinical Trial.

4

The treatment of advanced prostate cancer with ketoconazole: safety issues.

Bok RA, Small EJ. Bok RA, et al. Drug Saf. 1999 May;20(5):451-8. doi: 10.2165/00002018-199920050-00005. Drug Saf. 1999. PMID: 10348095 Review.

5

Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.

Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, Kantoff P, Shuman MA, Small EJ. Bok RA, et al. Cancer Res. 2001 Mar 15;61(6):2533-6. Cancer Res. 2001. PMID: 11289126

6

Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer.

Small EJ, Bok R, Reese DM, Sudilovsky D, Frohlich M. Small EJ, et al. Among authors: bok r. Semin Oncol. 2001 Aug;28(4 Suppl 15):71-6. doi: 10.1016/s0093-7754(01)90159-9. Semin Oncol. 2001. PMID: 11685733 Clinical Trial.

7

Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.

Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ. Harris KA, et al. J Urol. 2002 Aug;168(2):542-5. J Urol. 2002. PMID: 12131305

8

Bloodborne biomolecular markers in prostate cancer development and progression.

Bok RA, Small EJ. Bok RA, et al. Nat Rev Cancer. 2002 Dec;2(12):918-26. doi: 10.1038/nrc951. Nat Rev Cancer. 2002. PMID: 12459730 Review.

9

Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer.

Rini BI, Weinberg V, Bok R, Small EJ. Rini BI, et al. Among authors: bok r. J Clin Oncol. 2003 Jan 1;21(1):99-105. doi: 10.1200/JCO.2003.04.163. J Clin Oncol. 2003. PMID: 12506177 Clinical Trial.

10

Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma.

Rini BI, Weinberg V, Shaw V, Scott J, Bok R, Park JW, Small EJ. Rini BI, et al. Among authors: bok r. Cancer. 2004 Jul 1;101(1):90-5. doi: 10.1002/cncr.20313. Cancer. 2004. PMID: 15221993 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

141 results

Search Page

Filters